Vera posts positive Phase 3 rare kidney disease data, but crowded market loomsnews2025-06-02T10:30:08+00:00June 2nd, 2025|Endpoints News|
#ASCO25: In race with Merus, Bicara makes the case for two-year survival datanews2025-06-01T17:12:20+00:00June 1st, 2025|Endpoints News|
#ASCO25: AstraZeneca details Phase 3 data for oral SERD ‘switching’ regimennews2025-06-01T12:00:58+00:00June 1st, 2025|Endpoints News|
#ASCO25: Researchers debate how best to use checkpoint drugs in earlier cancersnews2025-06-01T12:00:24+00:00June 1st, 2025|Endpoints News|
#ASCO25: Takeda, Protagonist unveil data for rare blood disease drugnews2025-06-01T12:00:10+00:00June 1st, 2025|Endpoints News|
#ASCO25: Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underwaynews2025-05-31T12:00:59+00:00May 31st, 2025|Endpoints News|
#ASCO25: Enhertu extends life by three months for some stomach cancer patientsnews2025-05-31T12:00:27+00:00May 31st, 2025|Endpoints News|
#ASCO25: Gilead, Merck reveal ‘practice-changing’ data for Trodelvy-Keytruda combo in aggressive breast cancernews2025-05-31T12:00:22+00:00May 31st, 2025|Endpoints News|
#ASCO25: Arvinas, Pfizer’s PROTAC in breast cancer no better than oral SERDsnews2025-05-31T12:00:14+00:00May 31st, 2025|Endpoints News|
Summit’s disappointing survival readout raises stakes for full datanews2025-05-30T15:46:15+00:00May 30th, 2025|Endpoints News|
